Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Cited by (192)

Items 101–192 of 192

1. Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV ‐2 variants?
   Daniele Focosi, Massimo Franchini, Michael J. Joyner, Arturo Casadevall · 2022 · Vox Sanguinis
2. Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
   Danmei Su, Xinglin Li, Cui He, Xueqing Huang, Meiling Chen, Qiang Wang, Wenchang Qin, Ying Shi Liang, Rong Xu, Jinhua Wu et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
3. SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors
   Asma Asghar, Hafiz Muhammad Imran, Naheed Bano, Sadia Maalik, Sajida Mushtaq, Asim Hussain, Sunita Varjani, Lotfi Aleya, Hafiz M.N. Iqbal, Muhammad Bilal · 2022 · Environmental Science and Pollution Research
4. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern
   Ziyan Wang, Jiao An, Kunpeng Liu, Pin Yü, Xin De Fang, Jiadai Li, Huachen Zhu, Qianjun Zhu, Chuanqi Huang, Chao Zhang et al. · 2022 · npj Vaccines
5. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2
   Ingrid Siciliano Horbach, Adriana de Souza Azevedo, Waleska Dias Schwarcz, Nathalia dos Santos Alves, Brenda de Moura Dias, Bruno Pimenta Setatino, Luma da Cruz Moura, Ariane Faria de Souza, Caio Bidueira Denani, Stephanie Almeida da Silva et al. · 2024 · Diseases
6. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
   Adam V. Wisnewski, Carrie A. Redlich, Kathy Kamath, Queenie-Ann Abad, Richard Smith, Louis E. Fazen, Romero Santiago, Jian Liu, Julian Campillo Luna, Brian Martinez et al. · 2021 · PLoS ONE
7. SARS‐CoV‐2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice
   Yao Ma, Ye Wang, Chunhong Dong, Gilbert X. Gonzalez, Wandi Zhu, Joo Kim, Lai Wei, Sang‐Moo Kang, Bao‐Zhong Wang · 2022 · Small
8. What makes SARS‐CoV‐2 unique? Focusing on the spike protein
   Jingbo Qian, Shi-Chang Zhang, Fang Wang, Jinming Li, Jiexin Zhang · 2024 · Cell Biology International
9. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques
   Margherita Rosati, Mahesh Agarwal, Xintao Hu, Santhi Devasundaram, Dimitris Stellas, Bhabadeb Chowdhury, Jenifer Bear, Robert Burns, Duncan E. Donohue, Laurent Pessaint et al. · 2021 · PLoS Pathogens
10. Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike
    Toong Seng Tan, Mako Toyoda, Hirotaka Ode, Godfrey Barabona, Hiroshi Hamana, Mizuki Kitamatsu, Hiroyuki Kishi, Chihiro Motozono, Yasumasa Iwatani, Takamasa Ueno · 2022 · Journal of Virology
11. Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms
    Diego M. Cantoni, Gabriel Siracusano, Martin Mayora Neto, Claudia Pastori, Tobia Fantoni, Spyros Lytras, Cecilia Di Genova, Joseph Hughes, on behalf of the Ambulatorio Medico San Luca Villanuova Group, Lucia Lopalco et al. · 2022 · Vaccines
12. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
    Alessio Alesci, Marco Gitto, Magdalena Kotańska, Patrizia Lo Cascio, Anthea Miller, Noemi Nicosia, Angelo Fumia, Simona Pergolizzi · 2022 · Human Immunology
13. A Modular Biomaterial Scaffold‐Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS‐CoV‐2 Antigens
    Fernanda Langellotto, Maxence O. Dellacherie, Chyenne D. Yeager, Hamza Ijaz, Jingyou Yu, Chi‐An Cheng, Nikolaos Dimitrakakis, Benjamin T. Seiler, Makda S. Gebre, Tal Gilboa et al. · 2021 · Advanced Healthcare Materials
14. COVIDSeq as Laboratory Developed Test (LDT) for Diagnosis of SARSCoV- 2 Variants of Concern (VOC)
    Rob E. Carpenter, Vaibhav Kumar Tamrakar, Sadia Almas, Emily Brown, Rahul Sharma · 2022 · Archives of Clinical and Biomedical Research
15. Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine
    Sivaprakasam T. Selvavinayagam, Yean Kong Yong, Hong Yien Tan, Ying Zhang, Gurunathan Subramanian, Manivannan Rajeshkumar, Vasudevan Kalaivani, Priyanka Jayapal, Krishnasamy Narayanasamy, Dinesh Ramesh et al. · 2022 · Frontiers in Medicine
16. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era
    Ender Volkan · 2021 · Molecular Biotechnology
17. SARS-CoV-2 variants, a still unfinished story
    Marta Pérez-Abeledo, J.C. Sanz Moreno · 2021 · Vacunas (English Edition)
18. Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
    Etsuro Nanishi, Francesco Borriello, Hyuk‐Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Jing Chen, Joann Diray‐Arce, Kijun Song, Andrew Z. Xu et al. · 2023 · npj Vaccines
19. SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
    Ralf Duerr, Keaton M. Crosse, Ana M. Valero-Jimenez, Meike Dittmann · 2021 · Microorganisms
20. SARS-CoV-2 spike protein N501Y mutation causes differential species transmissibility and antibody sensitivity: a molecular dynamics and alchemical free energy study
    Xu-Dong Hou, Zhilin Zhang, Jiali Gao, Yingjie Wang · 2021 · Molecular Systems Design & Engineering
21. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs
    Busen Wang, Jinghan Xu, Shipo Wu, Zhe Zhang, Zhenghao Zhao, Jun Zhang, Ling Lin Fu, Xiaodong Zai, Yudong Wang, Guanying Zhang et al. · 2022 · Signal Transduction and Targeted Therapy
22. ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus
    Christian Albert Devaux, Jacques Fantini · 2023 · Frontiers in Microbiology
23. Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
    Amy C Sherman, Michaël Desjardins, Lindsey Robert Baden · 2021 · Clinics in Laboratory Medicine
24. Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis
    Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Ruijia Sun, Wanying Lu, Nan Zheng, Jiaxin Zhou, Qianhui Wu, Xiaowei Deng, Zeyao Zhao et al. · 2021 · SSRN Electronic Journal
25. SARS-CoV-2 Next Generation Sequencing (NGS) data from clinical isolates from the East Texas Region of the United States
    Rob E. Carpenter, Vaibhav Kumar Tamrakar, Sadia Almas, Aditya Sharma, Rahul Sharma · 2023 · Data in Brief
26. Investigation of SARS-CoV-2 Epsilon Variant and Hospitalization Status by Genomic Surveillance in a Single Large Health System During the 2020-2021 Winter Surge in Southern California
    Shangxin Yang, Peera Hemarajata, Evann E. Hilt, Travis K. Price, Omai B. Garner, Nicole M. Green · 2021 · American Journal of Clinical Pathology
27. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD
    Endah Puji Septisetyani, Pekik Wiji Prasetyaningrum, Khairul Anam, Adi Santoso · 2021 · Immune Network
28. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
    Longbo Hu, Yuhua Xu, Liping Wu, Jin Feng, Lu Zhang, Yongjie Tang, Xiang Zhao, Runming Mai, Liyun Chen, Lingling Mei et al. · 2022 · Viruses
29. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew J. Koch, Kathryn E. Foulds et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
30. Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany
    Sébastien Calvignac‐Spencer, Matthias Budt, Matthew R. Huska, Hugues Richard, Luca Leipold, Linus Grabenhenrich, Torsten Semmler, Max von Kleist, Stefan Kröger, Thorsten Wolff et al. · 2021 · Viruses
31. A superior heterologous prime‐boost vaccination strategy against COVID‐19: A bivalent vaccine based on yeast‐derived RBD proteins followed by a heterologous vaccine
    Yu Liu, Miao Li, Tingting Cui, Zhian Chen, Liangting Xu, Wenjuan Li, Qinhua Peng, Xingxing Li, Danhua Zhao, C. Alexander Valencia et al. · 2024 · Journal of Medical Virology
32. Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48 h post infection
    Jason Pearson, Timothy Wessler, Alex Chen, Richard C. Boucher, Ronit Freeman, Samuel K. Lai, Raymond John Pickles, M. Gregory Forest · 2023 · Journal of Theoretical Biology
33. Human Coronaviruses: Counteracting the Damage by Storm
    Dewald Schoeman, Burtram Clinton Fielding · 2021 · Viruses
34. Environmental Surveillance for SARS-CoV-2 in Two Restaurants from a Mid-scale City that Followed U.S. CDC Reopening Guidance
    Hongwan Li, Sripriya Nannu Shankar, Chiran T. Witanachchi, John A. Lednicky, Julia C. Loeb, Md. Mahbubul Alam, Z. Hugh Fan, Karim Mohamed, Jessica A. Boyette, Arantzazu Eiguren-Fernandez et al. · 2021 · Aerosol and Air Quality Research
35. Prediction of Putative Potential Sirnas for Inhibiting SARS-CoV-2 Strains, Including Variants of Concern and Interest
    Abdullah Al Saba, Maisha Adiba, Sajib Chakraborty, AHM Nurun Nabi · 2022 · Future Microbiology
36. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
    Lu Zhang, Hongquan Chen, Su Lan Yang, Yang Zhao, Xiaoyun Y. Shen, Xiaowen He, Haohui Ye, Deqin Wang, Jiazhou Lou, Yinshan Wang et al. · 2022 · Frontiers in Immunology
37. A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques
    Narach Khorattanakulchai, Kanjana Srisutthisamphan, Balamurugan Shanmugaraj, Suwimon Manopwisedjaroen, Kaewta Rattanapisit, Chalisa Panapitakkul, Taratorn Kemthong, Nutchanat Suttisan, Suchinda Malaivijitnond, Arunee Thitithanyanont et al. · 2022 · Frontiers in Plant Science
38. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
    Alona Kuzmina, Dina Korovin, Ido Cohen-Lass, Nofar Atari, Aner Ottolenghi, Pan Hu, Michal Mandelboim, Benyamin Rosental, Elli Rosenberg, Felipe Diaz‐Griffero et al. · 2023 · Heliyon
39. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
    Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez‐Cordón, Joanna Luczkowiak, Rafael Bastos Delgado, José M. Casasnovas, Mariano Estéban et al. · 2023 · Frontiers in Immunology
40. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
    Javier García‐Pérez, María González-Pérez, María Castillo de la Osa, Alberto Manuel Borobia, Luis Antonio Castaño, M.J. Bertran, Magda Campins, Antonio Portolés, David Lora, Mercedes Bermejo et al. · 2022 · EClinicalMedicine
41. Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model
    Shannon Stone, Amany Elsharkawy, J. D. Burleson, Mary J. Hauser, Arban Domi, Pratima Kumari, Zainab Nabi, Janhavi Prasad Natekar, Maciel Porto, Brian T. Backstedt et al. · 2025 · Vaccines
42. Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City
    Elizabeth V. Robilotti, Karissa A. Whiting, Anabella Lucca Bianchi, Chester Poon, Rebecca Guest, Tracy A. McMillen, Krupa Jani, Alexander Solovyov, Suzanne Kelson, Kevin Browne et al. · 2021 · Clinical Infectious Diseases
43. Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 Variants
    George Luo, Zhongbo Hu, John J. Letterio · 2021 · medRxiv
44. Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
    Gonzalo Almanza, Alex E. Clark, Valentina L. Kouznetsova, Eduardo Olmedillas, Andrea Castro, Igor F. Tsigelny, Yan Wu, George F. Gao, Sandra Lawrynowicz Leibel, William A. Bray et al. · 2022 · PLoS Pathogens
45. Comparison of 10 emerging SARS-CoV-2 Variants: infectivity, animal tropism, and antibody neutralization
    Zhang, Li, Cui, Zhimin, Li, Qianqian, Yu, Yuanling, Wu, Jiajing, Nie, Jianhui, Ding, Ruxia, Wang, Haixin, Zhang, Yue, Liu, Shuo et al. · 2021
46. A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays
    Tal Gilboa, Limor Cohen, Chi‐An Cheng, Roey Lazarovits, Augusta Uwamanzu‐Nna, Isaac Han, Kettner Griswold, Nick Barry, David B. Thompson, Richie E. Kohman et al. · 2021 · Angewandte Chemie
47. Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination
    Ece Tavukçuoğlu, Hamdullah Yanık, Mubaida Parveen, Sıla Ulutürk, Mine Durusu Tanrıöver, Ahmet Çağkan İnkaya, Murat Akova, Serhat Ünal, Güneş Esendağlı · 2023 · Scientific Reports
48. Genomic Diversity and Evolution of SARS-CoV-2 Lineages in Pakistan
    Muhammad Waqar Aziz, Nadia Mukhtar, Aftab Ahmad Anjum, Muhammad Hassan Mushtaq, Muhammad Adnan Ashraf, Amar Nasir, Muhammad Furqan Shahid, Muhammad Nawaz, Muhammad Zubair Shabbir, Noreen Sarwar et al. · 2023 · Viruses
49. Coronavirus Entry Inhibitors
    Qiaoshuai Lan, Shuai Xia, Lu Lu · 2022 · Advances in experimental medicine and biology
50. The importance of time post-vaccination in determining the decrease in vaccine efficacy against SARS-CoV-2 variants of concern
    Yinon M. Bar‐On, Εlad Noor, Noam Gottlieb, Alex Sigal, Ron Milo · 2021 · medRxiv
51. P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants
    Alona Kuzmina, Nofar Atari, Aner Ottolenghi, Dina Korovin, Ido Cohen-Lass, Benyamin Rosental, Elli Rosenberg, Michal Mandelboim, Ran Taube · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
52. Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal
    Haixin Wang, Li Zhang, Zi-teng Liang, Jianhui Nie, Jia-jing Wu, Qian-qian Li, Ruxia Ding, Yue Zhang, Guoqing Chen, Youchun Wang et al. · 2022 · Archives of Virology
53. Neutralization assays for SARS-CoV-2
    Labanya Mukhopadhyay, Nivedita Gupta, Pragya Dhruv Yadav, Neeraj Aggarwal · 2022 · The Indian Journal of Medical Research
54. Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
    Pratha Sah, THOMAS NOGUEIRA VILCHES, Affan Shoukat, Meagan C. Fitzpatrick, Abhishek Pandey, Burton H. Singer, Seyed M. Moghadas, Alison P. Galvani · 2021 · medRxiv
55. Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2
    Xiaorong Huang, Chumin Liang, Manman Li, Huimin Chen, Zhaowan Li, Qianqian Ruan, Ximing Hu, Lilian Zeng, Huifang Lin, Wei Zhao et al. · 2023 · Vaccines
56. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design
    Sing‐Han Huang, Yi-Ting Chen, Xiang-Yu Lin, Yi-Yi Ly, Ssu-Ting Lien, Pei-Hsin Chen, Cheng-Tang Wang, Suh‐Chin Wu, Chwen-Cheng Chen, Ching‐Yung Lin · 2023 · Scientific Reports
57. Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques
    Bryce M. Warner, Mable Chan, Nikesh Tailor, Robert Vendramelli, Jonathan Audet, Courtney Erin Meilleur, Thang Truong, Lauren Garnett, Marnie Willman, Geoff Soule et al. · 2024 · Vaccines
58. Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation
    Sara Caucci, Benedetta Corvaro, Sofia Maria Luigia Tiano, Anna Valenza, Roberta Longo, Katia Marinelli, Monica Lucia Ferreri, Patrik Spiridigliozzi, Giovanna Salvoni, Patrizia Bagnarelli et al. · 2021 · Vaccines
59. Broadly neutralizing antibodies against SARS-CoV-2 variants
    Linqi Zhang · 2022 · National Science Open
60. SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant
    Ferran Tarrés-Freixas, Benjamin Trinité, Anna Pons-Grífols, Miguel Romero‐Durana, Eva Riveira‐Muñoz, Carlos Ávila‐Nieto, Mónica Pérez, Edurne García-Vidal, Daniel Perez‐Zsolt, Jordana Muñoz‐Basagoiti et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
61. An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice
    Francesco Borriello, Etsuro Nanishi, Hyuk‐Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Robert E. Haupt, Jing Chen, Joann Diray‐Arce, Kijun Song et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
62. Modeling predicts mechanisms altered by mutations of the SARS-CoV-2 delta and omicron variants
    Jason Pearson, Timothy Wessler, Alex Chen, Richard C. Boucher, Ronit Freeman, Samuel K. Lai, Raymond John Pickles, M. Gregory Forest · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
63. A New Polymorphic Comprehensive Model for COVID-19 Transition Cycle Dynamics with Extended Feed Streams to Symptomatic and Asymptomatic Infections
    Yas Al‐Hadeethi, Intesar F. El Ramley, Hiba Mohammed, Abeer Z. Barasheed · 2023 · Mathematics
64. A Review on Variant of Concern (Delta Variant of COVID 19)
    Kanchan K. Jangam, Dattaprasad N. Vikhe, Ravindra S. Jadhav, Ganesh S. Shinde · 2022 · Asian Journal of Research in Pharmaceutical Sciences
65. Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
    Ludwig Knabl, Hye‐Kyung Lee, Manuel Wieser, Anna Mur, August Felix Zabernigg, Ludwig Knabl, Simon Rauch, Matthias Böck, Jana Schumacher, Norbert Kaiser et al. · 2021 · medRxiv
66. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis
    Evan J. Anderson, Lisa A. Jackson, Nadine Rouphael, Alicia T. Widge, David C. Montefiori, Nicole A. Doria‐Rose, Mehul S. Suthar, Kristen W. Cohen, Sarah E. O’Connell, Mat Makowski et al. · 2022 · Research Square
67. A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters
    Weina Sun, Yonghong Liu, Fatima Amanat, Irene González‐Domínguez, Stephen McCroskery, Stefan Slamanig, Lynda Coughlan, Victoria C. Rosado, Nicholas Lemus, Sonia Jangra et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
68. Treatment and therapeutic agents
    Iqra Naveed Akhtar · 2021 · Elsevier eBooks
69. Risk Factors for Breakthrough Acute SARS‐CoV‐2 Infections in Fully Vaccinated Individuals: A Case‐Control Study Nested in a Prospective Cohort in Medelln, Colombia
    Olga Hernández, Andrés Felipe Naranjo, Juan José Vélez Cadavid, Gisela de la Rosa Echavez, Sara Moreno‐Bedoya, BLADIMIR ALEJANDRO GIL VALENCIA, Jorge E. Sará Ochoa, Francisco Molina Saldarriaga, A. Melissa Moreno, Laura S. Perez‐Restrepo et al. · 2025 · Journal of Medical Virology
70. Production of SARS-CoV-2 virus-like particles as a vaccine candidate in stable cell lines through inducible E and M protein expression
    Yu Liu, Zhian Chen, Yang Li, Chunmei Gan, Jieshi Tang, Zhaoyue Zheng, Jingya Ye, C. Alexander Valencia, Hoi Yee Chow, Biao Dong · 2025 · BMC Biotechnology
71. Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review
    Vivek P. Chavda, Anita A. Mehta, Hajra Zafar, Faisal Raza, Ana Cláudia Paiva‐Santos, Pankti C. Balar, Vasso Apostolopoulos, Lalitkumar K. Vora · 2025 · Frontiers in Bioscience-Landmark
72. Stable and durable antibody responses in SARS‐recovered donors vaccinated with inactivated SARS‐CoV‐2 vaccine
    Tingting Jia, Yuankai Wu, Guancheng Liao, Yuxuan Lei, Zhengyu Wu, Fangji Yang, Jiamin Chen, Qian Xie, Chuming Luo, Yutian Chong et al. · 2023 · Journal of Medical Virology
73. Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?
    Shima Tavakol, Hani Tavakol, Mohammad S. Alavijeh, Alexander Marcus Seifalian · 2022 · Current Pharmaceutical Design
74. Genomics and epidemiology of SARS-CoV-2 lineage
    Sayaka Sukegawa, Hiroaki Takeuchi · 2021 · Uirusu
75. COVID-19 mRNA Vaccines
    Yuan‐Yeu Yau, Subhrajyoti Mishra, Mona Easterling, Ashwani Kumar · 2022 · Springer eBooks
76. A retrospective cross-sectional observational study of SARS-CoV-2 reinfection in La Ribera Health Department, Valencia, Spain
    S.L. Belloch García · 2022 · Journal of Medical Microbiology
77. Isolation and characterization of SARS-CoV-2 VOC, 20H/501Y.V2, from UAE travelers
    Pragya Dhruv Yadav, Prasad Sarkale, Alpana Razdan, Nivedita Gupta, Dimpal A. Nyayanit, Rima Rakeshkumar Sahay, Varsha Atul Potdar, Deepak Y. Patil, Shreekant Baradkar, Abhinendra Kumar et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
78. Broad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in mice
    Chotiwat Seephetdee, Kanit Bhukhai, Nattawut Buasri, Puttipatch Leelukkanaveera, Pat Lerdwattanasombat, Suwimon Manopwisedjaroen, Nut Phueakphud, Sakonwan Kuhaudomlarp, Eduardo Olmedillas, Erica Ollmann Saphire et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
79. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and natural immunity
    Lauren J. Beesley, Kelly R. Moran, Kshitij Wagh, Lauren A Castro, James P. Theiler, Hyejin Yoon, Will Fischer, Nicolas Hengartner, Bette Korber, Sara Y. Del Valle · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
80. Infectivity and Antigenicity of SARS-CoV-2 Strains in Portugal
    Weijin Huang, Haixin Wang, Li Zhang, Ziteng Liang, Jianhui Nie, Jiajing Wu, qian-qian li, Ruxia Ding, yue zhang, Guoqing Chen et al. · 2021 · Research Square
81. Most Concern Strains of Coronavirus-2 and Diagnostic Protocol in Iraqi’s Hospitals: A review
    Hadeel Kareem Musafer, Raghad A. Abdulrazaq, Majid Ahmed AL-Bayati, Sadeq Abdulridha Gatea Kaabi, Bashar Abdulateef · 2022 · Mağallaẗ ʻulūm al-rāfidayn
82. Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines
    Evan J. Anderson, Lisa A. Jackson, Nadine Rouphael, Alicia T. Widge, David C. Montefiori, Nicole A. Doria‐Rose, Mehul S. Suthar, Kristen W. Cohen, Sarah E. O’Connell, Mat Makowski et al. · 2022 · Research Square
83. First Case of COVID-19 N501Y Variant of Concern Infection in a Patient with Chronic HIV Infection
    Wen Qing Ye, Joanne Britto, John Neary, Mark Andrew Crowther · 2021 · Canadian Journal of General Internal Medicine
84. SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
    Aarthi Goverdhan · 2023 · Elsevier eBooks
85. Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variants
    Kshitij Wagh, Xiaoying Shen, James P. Theiler, Bethany Girard, Jean-Claude A. Marshall, David C. Montefiori, Bette Korber · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
86. Clinical characteristics, management, and prevention of coronavirus disease 2019
    Wei‐jie Guan, Jianxing He · 2023 · Frigid Zone Medicine
87. Development of plant-produced subunit vaccines to elicit the immunogenicity against SARS-CoV-2 variant viruses
    Narach Khorattanakulchai, Waranyoo Phoolcharoen · 2022 · Chula Digiverse
88. Research on Variation of Sars-Cov-2 and Rapid Detection
    Jiashu Jiang, Virgia Wang · 2023 · International Conference on Bioinformatics and Biomedical Technology (ICBBT)
89. Tracking SARS-CoV-2 variants in Kurdistan Region of Iraq.
    Pyman Mohamed Mohamedsalih, Karzan Jalal Salih, Banaz Omar Kareem, Dana Khdr Sabir · 2023 · ZANCO Journal of Pure and Applied Sciences
90. Association of RBD mutations with COVID-19 disease severity in the Iranian population
    Mozhgan Mondeali, Mohamad Mahjoor, Mansoor Khaledi, Ahdiyeh Saghabashi, Seyedeh Faride Alavi Rostami, Mohammad Hossein Modarressi · 2025 · Virus Genes
91. Epitope Profiling of SARS-CoV-2 Spike Antigen Provides a Novel Strategy for Developing ELISAs Specific for Different Spike Protein Variants in Bivalent Vaccine Formulations
    Luciano Ettorre, Trevor Williams, Camille Houy, Shaolong Zhu, Michael Kishko, Ali Azizi, D. Andrew James, Beata Gajewska, Jason Szeto · 2025 · Vaccines
92. Safety and immunogenicity of NDV-HXP-S, phase 1 trial
    Bruce Innis · 2024 · ImmPort